TNYA - Tenaya Therapeutics, Inc. Stock Analysis | Stock Taper

SCREENER COMPARE ANY 2 STOCKS

TNYA

TENAYA THERAPEUTICS, INC.

NASDAQ

$0.69

▼ DOWN 0.73% (-0.01)

KEY STATISTICS

Market Cap$149.75 M

52w High$2.35

52w Low$0.53

Dividend Yield—

Frequency—

P/E-1.30

Volume1.10M

Shares Out.217.00M

COMPANY

LEADERSHIP

Faraz Ali

CHIEF EXECUTIVE

Faraz Ali

COMPENSATION 2026

Salary$664,173

Stock Awards$141,924

Incentive Plan Pay$319,275

All Other Comp.$516

Total$1,881,396

ABOUT

SECTOR

Healthcare

WENT PUBLIC

July 30, 2021

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

70

PRICE TARGET

Target High$2.00

Target Low$2.00

Target Median$2.00

Target Consensus$2.00

UPCOMING EARNINGS

DateNov 11, 2026

DayWednesday

Rev. Est.$802.50K

NOV

11

WED

PRICE

$0.69 ▼ DOWN 0.73% (−$0.01)

About Tenaya Therapeutics, Inc.

https://www.tenayatherapeutics.com ↗

Tenaya Therapeutics is a biotech company developing gene therapies, small molecules, and regenerative treatments for various heart diseases, including gHCM, HFpEF, gDCM, and arrhythmogenic cardiomyopathies.

INDUSTRY

Biotechnology

A PRODUCT TENAYA THERAPEUTICS, INC. IS KNOWN FOR

TN-201

TN-201

TN-201 is a Phase 1b/2 AAV-based gene therapy by Tenaya targeting MYBPC3-associated hypertrophic cardiomyopathy by delivering a functional MYBPC3 gene to heart cells.

COMPETITORS

COMPETITOR

ETFS HOLDING THIS STOCK

ETFS HOLDING

23

LISTED HERE

5

RANKED BY POSITION SIZE

0.01% · 221.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED

26.56%

HOLDERS

143

TOP 12 OF 143 · RANKED BY POSITION SIZE

Column Group LLC

9.4M sh · $6.69M

Vanguard Group Inc

8.6M sh · $6.09M

Millennium Management LLC

5.5M sh · $3.78M

Empery Asset Management, LP

5.4M sh · $3.85B

Citadel Advisors LLC

4.2M sh · $2.99M

Anson Funds Management LP

4.2M sh · $2.95M

4.1M sh · $12.63M

Alyeska Investment Group, L.P.

4.0M sh · $2.85M

Blackrock, Inc.

3.9M sh · $2.81M

Renaissance Technologies LLC

3.7M sh · $2.57M

Marshall Wace, Llp

2.7M sh · $1.87M

Burkehill Global Management, LP

2.0M sh · $1.38M

RATINGS SNAPSHOT

Overall rating: C+

Discounted Cash Flow4

Return On Equity1

Return On Assets1

Debt To Equity3

Price To Earnings1

Price To Book3

Overall Score2

INSIDER TRADES

★

DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER

Ali Faraz

Sale · 5.0K shares

2026-08-17

★

DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER

Ali Faraz

Sale · 7.4K shares

2026-08-17

★

OFFICER: CHIEF MEDICAL OFFICER

Tingley Whittemore

Sale · 2.3K shares

2026-08-17

★

DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER

Ali Faraz

Sale · 5.8K shares

2026-08-17

MOST RECENT ANALYST GRADES

GRADE SUMMARY

BUY 3

3 GRADES IN THE LAST 12 MONTHS

Chardan Capital BUY

Canaccord Genuity BUY

HC Wainwright & Co. BUY

SECTORS PEERS

PEER	PRICE
PRLD	$5.47	COMPARE
ENTA	$13.60	COMPARE
FHTX	$6.00	COMPARE
ABEO	$5.92	COMPARE
VYGR	$3.54	COMPARE
PYXS	$3.23	COMPARE
IMRX	$4.99	COMPARE
CRBU	$1.62	COMPARE